Investorideas.com | big ideas for the small cap investor- One of the first online investor resources providing research tools for renewable energy, water and Homeland Security Investing Search www.investorideas.com

join login services submit news

   Membership       Stock Alerts       Featured Stocks       Newsletter       Research       News       Green Investor       Stock Directories       Funding       Services     

Investor Ideas - www.InvestorIdeas.com.com - Become a Smart Investor Member and join today!
For more information on joining our Smart Investor Membership, click here



Exclusive Audio Interviews

Exclusive Articles

  • The scientific community and general public have expressed increasing concern over whether a virulent strain of Avian Flu (H5N1) could extend to reach a pandemic proportion, in our near future. Biotech and Healthcare companies: Bridgetech Holdings International Inc (OTC.PK: BGTH), Generex Biotech (NASDAQ: GNBT), AVI Biopharma Inc., Hemispherx Biopharma (AMEX: HEB), Inc, Carrington Laboratories (NasdaqNM: CARN) and Aethlon Medical (OTCBB: AEMD), discuss unique approaches to this potential global dilemma and offer insight to possible solutions. click here
  • Chasing the Blues from Your Portfolio posted March 9, 2006 (CORT) The next time you hear people moan about a tough day, you might remind them they should at least be happy they don’t have a problem that doctors call psychotic major depression (PMD). click here
  • Custom Cancer Care With a Little Help from Giant Sea Snails posted March 2, 2006 (GTOP) One of the reasons we succumb to cancer so easily is that our immune systems are reluctant to attack it. Since tumors are a part of us, killing them is tantamount to self destruction, at least from the point of view of an immune system. click here
  • Snipping Genes to Cure Diseases By Michael Brush February 09, 2006 - Alnylam Pharmaceuticals (ALNY) - When U.S. President George Bush asked Congress to write laws that would ban “human-animal” hybrids last week in his State of the Union speech, it was a chilling reminder of the more bizarre implications of the genetic research going on around us. click here
  • Training Special Forces Units to Fight Cancer By Michael Brush, October 06, 2005 - Oxigene (OXGN) - Many investors avoid biotech stocks out of sheer habit. They were either burned by this notoriously volatile sector in the past. They are leery of money-losing companies that may have to do a dilutive financing. Or they know that even analysts who master the intricacies of the science behind drug development still have a tough time picking winners. click here
  • A Drug That Adds Pounds Can Also Fatten Your Wallet - By Michael Brush, August 11, 2005 In an age when most people are losing the battle to shed pounds, you might find it odd that there’s one pharmaceutical company staking its future on a drug that helps people gain weight. But a drug offered by Woodcliff Lake, NJ-based Par Pharmaceutical (PRX) to help people put on the pounds is no joke. click here
  • Insider Buying Says This May Be the Year for Hepatitis Cure Company posted February 10, 2005 - When news hit the wires in late January that SciClone Pharmaceuticals (SCLN) insiders were scooping up shares, the company’s stock wasted little time shooting to $3.75 from $3. click here
  • AstraZeneca Announces IRESSA Drug Fails Lung Cancer Trial dated 17th, 2004 December 17th, 2004 – InvestorIdeas.com – On Friday morning, following issuance of a statement that their drug IRESSA failed to significantly prolong survival in patients with lung cancer, the share price of healthcare company AstraZeneca dropped by 8.7%. click here
  • Pfizer Inc. Releases Statement Regarding Cardiovascular Risks of Drug Celebrex dated December 17th, - www.InvestorIdeas.com – Pfizer Inc. (PFE) has released a statement declaring that use of their painkilling drug Celebrex by cancer patients could result in an increased risk of heart problems. Dosing in long term cancer studies has been suspended by the National Cancer Institute, while the reported findings of two long-term cancer trials are analyzed. click here

Biotech Stock News

Biotech Stock Research

  • RNCOS Releases a New Report- Asia Pacific Biotechnology Market (2008-2012) - click here
  • Indian Biotech Market Gaining Traction from Biopharma - Click Here
  • Speculative Buy Recommendation for VICTHOM HUMAN BIONICS INC. (TSX: VHB) with 12 month target price of $1.40 per share - - Click Here
  • Research and Markets: Bio Ethanol and Bio Pharmaceuticals Industries Prop up the U.S. Industrial Enzymes Market - click here
  • RNCOS Releases a New Report- Emerging Pharmaceutical Markets Globally - click here
  • VICTHOM HUMAN BIONICS INC. (TSX:VHB) - RECENT DEVELOPMENTS: F2007 RESULTS; INTERIM PRESIDENT NAMED - click here
  • The US biotech market has been experiencing diverse changes for the past few years, but despite these changes, it is only booming - click here
  • RNCOS Releases a New Report- Booming Biotech Market in India - Click Here
  • Economic Growth, Improving Medical Infrastructure Backing E7 Pharma Markets - Click Here
  • Indian Biotechnology Market Outlook (2006) - India is fast becoming one of the most favored global destinations for biotechnology - click here
  • Point of Care Diagnostics to Chip in 34% in Global IVD Market - Click Here
  • Economical Cure - Generics to Penetrate 26% Pharma Market in Canada - Click Here
  • RNCOS Releases a New Report-Global In Vitro Diagnostic Market Analysis - Click Here
  • Price Differential, Patent Expirations Spurring Growth in US Generic Market - Click Here
  • Lifestyle Change Stipulating Growth in Indian Pharma Market - Click Here
  • Generics to Capture 23% Pharmaceutical Market in Brazil by 2011 - Click Here
  • RNCOS Releases Report on Generic Drug Market in Canada - Click Here
  • Speculative Buy Recommendation for IRI SEPARATION TECHNOLOGIES INC. (TSX.V: IRI) with the 12 month target price of $0.45 - Click Here
  • RNCOS Releases Report on Booming US Generic Drug Market - Click Here
  • RNCOS Releases Report on Indian Pharma Sector Analysis - click here
  • The Markets for Antimicrobial Additives in Plastics Worldwide growth through increasing infections - click here
  • Skinvisible, Inc. (OTC BB: SKVI) – Initiating Coverage - A unique and attractive drug delivery systemwith a broad range of industry applications - click here
  • Speculative Buy Recommendation for CANNASAT THERAPEUTICS INC. (TSX-V: CTH) with the Target Price at $0.35 per share - RECENT DEVELOPMENT: PATENT APPROVED - click here
  • Speculative Buy Recommendation for ANAVEX LIFE SCIENCES CORPORATION (OTCBB: AVXL) with the 12-month Target Price at $6.50 per share - click here
  • RNCOS Releases Report on Generic Drugs Market in Brazil - click here
  • Energy Bill Biofuels Mandates Will Be Achievable with Biotechnology Advances - Click Here
  • RNCOS Releases Report on Booming Clinical Trials Market in India - click here
  • RNCOS Releases Report on Global Vaccine Market Outlook (2007-2010) - click here
  • U.S. Market for Environmental Biotechnology Products for Waste Treatment Worth $261.3 Million by 2013 - click here
  • Global Vaccine Market Poised for Billion Dollar Growth - click here
  • RNCOS Releases Report on Russian Pharma Sector - click here
  • Direct Life, Health and Medical Insurance Carriers in the US - click here
  • Response Biomedical Corporation Announces Third Quarter Results - Click Here
  • US Vaccine Market Extracting Vigor from Flu Vaccines - click here
  • Designing Future - India as the Most Potential Destination forClinical Trials - click here
  • Speculative Buy recommendation for VICTHOM HUMAN BIONICS INC(TSX: VHB)with a Target Price of $0.30 - click here
  • RNCOS releases Report on Asia Pacific Biotechnology Market - click here
  • India and China Providing Escape Velocity to Global Aerospace - click here
  • India - Dexterous Laboratory for Global Clinical Trials - click here
  • RNCOS Releases Report on Insulin Delivery Systems Market - click here
  • Speculative Buy recommendation for CANNASAT THERAPEUTICS INC(TSX-V:CTH)with a Target Price of $0.35 - Completes Phase I Clinical Trial - click here
  • Third quarter Update Report on Victhom Human Bionics Inc. (TSX: VHB) - click here
  • eResearch Initiates coverage on Bio Extraction Inc.(BXI: TSX-V) with a Speculative Buy, and a 12-month Target Price of 0.75 - click here 
  • Bioinformatics - New Potion for Biotech and Pharma Firms, says RNCOS - click here
  • Future of Global Protein Therapeutics Market Healthy, says RNCOS - click here
  • eResearch Initiates coverage on Victhom Human Bionics Inc. (VHB:TSX) with a Speculative Buy, and a 12-month Target Price of $0.30 and 5-year target price of $1.60 - click here 
  • India's Biotechnology Industry Blooming - click here
  • India: Biotech Industry Hit US$ 2 Billion Mark in 2006-07 - click here
  • Biotechnology - Planet's Next Big Opportunity - click here
  • 1st Quarter Update Report on AMDL, Inc. - click here
  • Mistral Pharma Inc. (TSX-V: MIP) Rated a Speculative Buy for high-risk accounts -click here
  • US Biotechnology Firms Grew Exponentially in 2006 - Year 2006 remained extraordinarily good for the US biotechnology firms. The firms were able to deliver rapid growth in revenues and earn huge profits. Biotechnology firms in US raised US$ 27.9 Billion in loans and investments in this year, maximum since 2000. This reflected the increasing alliances with drug makers of global industry. click here
  • Indian Stem Cell Market to Hit US$ 540 Million by 2010 - Growing at a rate of 15% per annum India's stem cell market is estimated to hit US$ 540 Million by the year 2010, while the global stem cell market is expected to touch US$ 20 Billion mark, said Dr D Balasubramaniam, SCRFI (Stem Cell Research Forum of India) president, in a statement that ChennaiOnline published on 30 January 2007. click here
  • India Leads Asian Biotech Sector - Clive James, Chairman, International Service for the Acquisition of Agri-biotech Applications (ISAAA), said in a statement as reported on February 20, 2007 by checkbiotech.org that India is fast evolving as a leading biotech region in Asia, outshining China for the first time in terms of total hectare land planted with biotechnology seeds.click here

Featured Articles By Industry Participants

  • Diabetics To Touch 325 Million By 2025 - Sedentary lifestyle and obesity being the main reasons, more and more people are falling prey to the deadly disease know as diabetes. click here
  • Part One: Will 'Linked Recognition' Lead to a Cancer Vaccine? While preparing a lecture in biochemistry and virology for his graduate students at the University of Alberta in the early 1980s, Dr. Lorne Tyrrell ran across a study just published in the medical journal, Cell. The research by William Mason and Jesse Summers, entitled "Replication of Hepatitis B," discussed their study of the hepatitis B virus in infected duck liver. click here
  • Could ViRexx's 'Linked Recognition' Research Lead to a Cancer Vaccine? Summary: Dr. Lorne Tyrrell pioneered lamivudine as the standard treatment for hepatitis B virus (HBV). Now a success, he observed the drug's shortcomings. Now CEO of ViRexx Medical, Tyrrell hopes his latest development, Chimigen, will offer new hope for HBV, other infectious diseases, and cancer. click here

News and Resources

Biotech Industry Associations

Conferences

Our site does not give specific recommendations and encourages investors to complete their own due diligence. Our lists are compiled from internal and external research sources. Our lists are to be used only as a partial source of due diligence.

TOP

Investor Ideas © 2000 - 2012 InvestorIdeas.com®, ECON

 Free Investor Stock Alerts
Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | videos | sitemap |